Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109


Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine.

Husain H, Melnikova VO, Kosco K, Woodward B, More S, Pingle SC, Weihe E, Park BH, Tewari M, Erlander MG, Cohen E, Lippman SM, Kurzrock R.

Clin Cancer Res. 2017 Aug 15;23(16):4716-4723. doi: 10.1158/1078-0432.CCR-17-0454. Epub 2017 Apr 18.


Variations in EGFR ctDNA Correlates to the Clinical Efficacy of Afatinib in Non Small Cell Lung Cancer with Acquired Resistance.

He J, Tan W, Tang X, Ma J.

Pathol Oncol Res. 2017 Apr;23(2):307-315. doi: 10.1007/s12253-016-0097-y. Epub 2016 Aug 11.


Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA.

Remon J, Caramella C, Jovelet C, Lacroix L, Lawson A, Smalley S, Howarth K, Gale D, Green E, Plagnol V, Rosenfeld N, Planchard D, Bluthgen MV, Gazzah A, Pannet C, Nicotra C, Auclin E, Soria JC, Besse B.

Ann Oncol. 2017 Apr 1;28(4):784-790. doi: 10.1093/annonc/mdx017.


Urinary circulating DNA detection for dynamic tracking of EGFR mutations for NSCLC patients treated with EGFR-TKIs.

Chen S, Zhao J, Cui L, Liu Y.

Clin Transl Oncol. 2017 Mar;19(3):332-340. doi: 10.1007/s12094-016-1534-9. Epub 2016 Jul 28.


Longitudinal monitoring of ctDNA EGFR mutation burden from urine correlates with patient response to EGFR TKIs: A case series.

Tchekmedyian N, Mudad R, Blanco FF, Raymond VM, Garst J, Erlander MG, Haura E, Berz D.

Lung Cancer. 2017 Jun;108:22-28. doi: 10.1016/j.lungcan.2017.02.010. Epub 2017 Feb 20.


Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib.

Ou SI, Cui J, Schrock AB, Goldberg ME, Zhu VW, Albacker L, Stephens PJ, Miller VA, Ali SM.

Lung Cancer. 2017 Jun;108:228-231. doi: 10.1016/j.lungcan.2017.04.003. Epub 2017 Apr 12.


EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs.

Liang Z, Cheng Y, Chen Y, Hu Y, Liu WP, Lu Y, Wang J, Wang Y, Wu G, Ying JM, Zhang HL, Zhang XC, Wu YL.

Cancer Lett. 2017 Sep 10;403:186-194. doi: 10.1016/j.canlet.2017.06.008. Epub 2017 Jun 19. Review.


Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.

Ishii H, Azuma K, Sakai K, Kawahara A, Yamada K, Tokito T, Okamoto I, Nishio K, Hoshino T.

Oncotarget. 2015 Oct 13;6(31):30850-8. doi: 10.18632/oncotarget.5068.


Utility of urinary circulating tumor DNA for EGFR mutation detection in different stages of non-small cell lung cancer patients.

Li F, Huang J, Ji D, Meng Q, Wang C, Chen S, Wang X, Zhu Z, Jiang C, Shi Y, Liu S, Li C.

Clin Transl Oncol. 2017 Oct;19(10):1283-1291. doi: 10.1007/s12094-017-1669-3. Epub 2017 May 11.


EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291.

Thress KS, Brant R, Carr TH, Dearden S, Jenkins S, Brown H, Hammett T, Cantarini M, Barrett JC.

Lung Cancer. 2015 Dec;90(3):509-15. doi: 10.1016/j.lungcan.2015.10.004. Epub 2015 Oct 9.


The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer.

Gao X, Le X, Costa DB.

Expert Rev Anticancer Ther. 2016;16(4):383-90. doi: 10.1586/14737140.2016.1162103. Epub 2016 Mar 21. Review.


Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA.

Thompson JC, Yee SS, Troxel AB, Savitch SL, Fan R, Balli D, Lieberman DB, Morrissette JD, Evans TL, Bauml J, Aggarwal C, Kosteva JA, Alley E, Ciunci C, Cohen RB, Bagley S, Stonehouse-Lee S, Sherry VE, Gilbert E, Langer C, Vachani A, Carpenter EL.

Clin Cancer Res. 2016 Dec 1;22(23):5772-5782. Epub 2016 Sep 6.


Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.

Sacher AG, Paweletz C, Dahlberg SE, Alden RS, O'Connell A, Feeney N, Mach SL, Jänne PA, Oxnard GR.

JAMA Oncol. 2016 Aug 1;2(8):1014-22. doi: 10.1001/jamaoncol.2016.0173. Erratum in: JAMA Oncol. 2016 Aug 1;2(8):1099.


Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.

Tan CS, Cho BC, Soo RA.

Lung Cancer. 2016 Mar;93:59-68. doi: 10.1016/j.lungcan.2016.01.003. Epub 2016 Jan 8. Review.


Monitoring of treatment responses and clonal evolution of tumor cells by circulating tumor DNA of heterogeneous mutant EGFR genes in lung cancer.

Imamura F, Uchida J, Kukita Y, Kumagai T, Nishino K, Inoue T, Kimura M, Oba S, Kato K.

Lung Cancer. 2016 Apr;94:68-73. doi: 10.1016/j.lungcan.2016.01.023. Epub 2016 Feb 2.


Dynamics of circulating tumor DNA represented by the activating and resistant mutations in epidermal growth factor receptor tyrosine kinase inhibitor treatment.

Uchida J, Imamura F, Kukita Y, Oba S, Kumagai T, Nishino K, Inoue T, Kimura M, Kato K.

Cancer Sci. 2016 Mar;107(3):353-8. doi: 10.1111/cas.12860. Epub 2016 Feb 18.


A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.

Yanagita M, Redig AJ, Paweletz CP, Dahlberg SE, O'Connell A, Feeney N, Taibi M, Boucher D, Oxnard GR, Johnson BE, Costa DB, Jackman DM, Jänne PA.

Clin Cancer Res. 2016 Dec 15;22(24):6010-6020. Epub 2016 Jun 8.


Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.

Yang X, Zhuo M, Ye X, Bai H, Wang Z, Sun Y, Zhao J, An T, Duan J, Wu M, Wang J.

Oncotarget. 2016 Apr 12;7(15):20810-24. doi: 10.18632/oncotarget.8021.

Supplemental Content

Support Center